MovDisordV3, France, Analysis, bibRecord, 000591

A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity

Identifieur interne : 000591 ( France/Analysis ); précédent : 000590; suivant : 000592

A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity

Auteurs : Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Montastruc [France]

Source :

Movement Disorders [ 0885-3185 ] ; 1997-05.

RBID : ISTEX:8B23AF0B4C78751EBFC17453B4C76B6C584D2395

Descripteurs français

Pascal (Inist)
- Activité, Amine oxidase (flavin-containing), Antiparkinsonien, Dose efficace, Homme, IMAO B, Mesure, Parkinson maladie, Randomisation, Relation dose réponse, Sélégiline, Thrombocyte, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Activity, Adult, Aged, Amine oxidase (flavin-containing), Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Blood Platelets (metabolism), Dose activity relation, Dose-Response Relationship, Drug, Effective dose, Female, Human, Humans, MAO, MAO B inhibitor, MAO inhibitors, Male, Measurement, Middle Aged, Monoamine Oxidase (blood), Monoamine Oxidase (metabolism), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Platelet, Platelets, Randomization, Selegiline, Selegiline (administration & dosage), Selegiline (pharmacology), Selegiline (therapeutic use), Treatment.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Selegiline.
- chemical , blood : Monoamine Oxidase.
- chemical , metabolism : Monoamine Oxidase.
- chemical , pharmacology : Antiparkinson Agents, Selegiline.
- chemical , therapeutic use : Antiparkinson Agents, Selegiline.
- drug therapy : Parkinson Disease.
- metabolism : Blood Platelets.
- Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged.

Abstract

A dose‐ranging study of selegiline was performed in patients with Parkinson's disease to determine the minimal dosage of the drug able to inhibit ≥95% of platelet monoamine oxidase (MAO) activity. Different doses of selegiline (5 or 10 mg daily, 10 or 20 mg weekly) were studied in four groups of six patients with Parkinson's disease. Platelet MAO activity was measured before and after 1 month's treatment with selegiline. The doses of 5 or 10 mg daily and 20 mg (i.e., 10 mg × 2) weekly induced a complete inhibition of platelet MAO‐B activity from day 7 to day 28 (96.0–99.5%). In contrast, platelet MAO‐B inhibition was only 75.9% of the basal value after a dosage of 10 mg weekly. These results demonstrate that 20 mg weekly is the minimal dosage of selegiline able to induce a maximal and long‐lasting inhibition of platelet MAO‐B activity in patients with parkinsonism. Further clinical trials are needed to investigate the clinical efficacy of this dose.

Url:

https://api.istex.fr/document/8B23AF0B4C78751EBFC17453B4C76B6C584D2395/fulltext/pdf

DOI: 10.1002/mds.870120305

Affiliations:

Links to Exploration step

ISTEX:8B23AF0B4C78751EBFC17453B4C76B6C584D2395

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity</title>
<author><name sortKey="Andreu, Nathalie" sort="Andreu, Nathalie" uniqKey="Andreu N" first="Nathalie" last="Andreu">Nathalie Andreu</name>
</author>
<author><name sortKey="Damase Ichel, Christine" sort="Damase Ichel, Christine" uniqKey="Damase Ichel C" first="Christine" last="Damase-Michel">Christine Damase-Michel</name>
</author>
<author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Montastruc" sort="Montastruc" uniqKey="Montastruc" last="Montastruc">Montastruc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8B23AF0B4C78751EBFC17453B4C76B6C584D2395</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1002/mds.870120305</idno>
<idno type="url">https://api.istex.fr/document/8B23AF0B4C78751EBFC17453B4C76B6C584D2395/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002E58</idno>
<idno type="wicri:Area/Istex/Curation">002E58</idno>
<idno type="wicri:Area/Istex/Checkpoint">003A52</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Andreu N:a:dose:ranging</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:9159721</idno>
<idno type="wicri:Area/PubMed/Corpus">004685</idno>
<idno type="wicri:Area/PubMed/Curation">004685</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004733</idno>
<idno type="wicri:Area/Ncbi/Merge">004C97</idno>
<idno type="wicri:Area/Ncbi/Curation">004C97</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004C97</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Andreu N:a:dose:ranging</idno>
<idno type="wicri:Area/Main/Merge">008457</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:97-0320611</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003263</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003561</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003294</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Andreu N:a:dose:ranging</idno>
<idno type="wicri:Area/Main/Merge">008649</idno>
<idno type="wicri:Area/Main/Curation">005428</idno>
<idno type="wicri:Area/Main/Exploration">005428</idno>
<idno type="wicri:Area/France/Extraction">000591</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity</title>
<author><name sortKey="Andreu, Nathalie" sort="Andreu, Nathalie" uniqKey="Andreu N" first="Nathalie" last="Andreu">Nathalie Andreu</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Damase Ichel, Christine" sort="Damase Ichel, Christine" uniqKey="Damase Ichel C" first="Christine" last="Damase-Michel">Christine Damase-Michel</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Montastruc" sort="Montastruc" uniqKey="Montastruc" last="Montastruc">Montastruc</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1997-05">1997-05</date>
<biblScope unit="vol">12</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="293">293</biblScope>
<biblScope unit="page" to="296">296</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">8B23AF0B4C78751EBFC17453B4C76B6C584D2395</idno>
<idno type="DOI">10.1002/mds.870120305</idno>
<idno type="ArticleID">MDS870120305</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activity</term>
<term>Adult</term>
<term>Aged</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Blood Platelets (metabolism)</term>
<term>Dose activity relation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Effective dose</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>MAO</term>
<term>MAO B inhibitor</term>
<term>MAO inhibitors</term>
<term>Male</term>
<term>Measurement</term>
<term>Middle Aged</term>
<term>Monoamine Oxidase (blood)</term>
<term>Monoamine Oxidase (metabolism)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Platelet</term>
<term>Platelets</term>
<term>Randomization</term>
<term>Selegiline</term>
<term>Selegiline (administration & dosage)</term>
<term>Selegiline (pharmacology)</term>
<term>Selegiline (therapeutic use)</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Monoamine Oxidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Monoamine Oxidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Blood Platelets</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Activité</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Antiparkinsonien</term>
<term>Dose efficace</term>
<term>Homme</term>
<term>IMAO B</term>
<term>Mesure</term>
<term>Parkinson maladie</term>
<term>Randomisation</term>
<term>Relation dose réponse</term>
<term>Sélégiline</term>
<term>Thrombocyte</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A dose‐ranging study of selegiline was performed in patients with Parkinson's disease to determine the minimal dosage of the drug able to inhibit ≥95% of platelet monoamine oxidase (MAO) activity. Different doses of selegiline (5 or 10 mg daily, 10 or 20 mg weekly) were studied in four groups of six patients with Parkinson's disease. Platelet MAO activity was measured before and after 1 month's treatment with selegiline. The doses of 5 or 10 mg daily and 20 mg (i.e., 10 mg × 2) weekly induced a complete inhibition of platelet MAO‐B activity from day 7 to day 28 (96.0–99.5%). In contrast, platelet MAO‐B inhibition was only 75.9% of the basal value after a dosage of 10 mg weekly. These results demonstrate that 20 mg weekly is the minimal dosage of selegiline able to induce a maximal and long‐lasting inhibition of platelet MAO‐B activity in patients with parkinsonism. Further clinical trials are needed to investigate the clinical efficacy of this dose.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
</region>
<settlement><li>Toulouse</li>
</settlement>
<orgName><li>Université Toulouse III - Paul Sabatier</li>
<li>Université de Toulouse</li>
</orgName>
</list>
<tree><country name="France"><noRegion><name sortKey="Andreu, Nathalie" sort="Andreu, Nathalie" uniqKey="Andreu N" first="Nathalie" last="Andreu">Nathalie Andreu</name>
</noRegion>
<name sortKey="Damase Ichel, Christine" sort="Damase Ichel, Christine" uniqKey="Damase Ichel C" first="Christine" last="Damase-Michel">Christine Damase-Michel</name>
<name sortKey="Montastruc" sort="Montastruc" uniqKey="Montastruc" last="Montastruc">Montastruc</name>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000591 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000591 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:8B23AF0B4C78751EBFC17453B4C76B6C584D2395
   |texte=   A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity

A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.